Current pharmacogenomic recommendations in chronic respiratory diseases: Is there a biomarker ready for clinical implementation?

References

• Khaltaev N. GARD, a new way to battle with chronic respiratory diseases, from disease oriented programmes to global partnership. J Thorac Dis. 2017;9(11):4676–4689.
   PubMed Web of Science ®Google Scholar
• Xie M, Liu X, Cao X, et al. Trends in prevalence and incidence of chronic respiratory diseases from 1990 to 2017. Respir Res. 2020;21(1):49.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Chronic respiratory diseases [Internet]. cited 2022 Feb 15]. Available from 2022 Feb 15: https://www.who.int/health-topics/chronic-respiratory-diseases#tab=tab_3.
   Google Scholar
• Hersh CP. Pharmacogenomics of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2019;13(5):459–470.
   PubMed Web of Science ®Google Scholar
• Nielsen AO, Jensen CS, Arredouani MS, et al. Variants of the ADRB2 Gene in COPD: systematic review and meta-analyses of disease risk and treatment response. COPD. 2017;14(4):451–460.
   PubMedGoogle Scholar
• Kersten ETG, Koppelman GH. Towards diversity in asthma pharmacogenetics. Lancet Child Adolesc Heal. 2021;5(12):838–839.
   Web of Science ®Google Scholar
• Ortega VE, Daya M, Szefler SJ, et al. Pharmacogenetic studies of long-acting beta agonist and inhaled corticosteroid responsiveness in randomised controlled trials of individuals of African descent with asthma. Lancet Child Adolesc Heal. 2021;5(12):862–872.
   Web of Science ®Google Scholar
• Oldham JM, Noth I, Martinez FJ. Pharmacogenetics and interstitial lung disease. Curr Opin Pulm Med. 2016;22(5):456–465.
   PubMed Web of Science ®Google Scholar
• Drent M, Wijnen P, Bast A. Pharmacogenetic variants and vitamin K deficiency: a risk factor or trigger for fibrosing interstitial pneumonias? Curr Opin Pulm Med. 2018;24(3):287–295.
   PubMed Web of Science ®Google Scholar
• Crommelin H, Vorselaars A, Van Der Vis J, et al. Pharmacogenetics of antitumor necrosis factor therapy in severe sarcoidosis. Curr Opin Pulm Med. 2020;26(3):267–276.
   PubMed Web of Science ®Google Scholar
• Tutton R. Pharmacogenomic biomarkers in drug labels: what do they tell us? Pharmacogenomics. 2014;15(3):297–304.
   PubMed Web of Science ®Google Scholar
• FDA. Genomics - Table of pharmacogenomic biomarkers in drug labeling center for drug evaluation and research. Food and Drug Administration; cited 2022 Feb 15]. Available from 2022 Feb 15: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling.
   Google Scholar
• pharmgkb.org [Internet]. cited 2022 Feb 15]. Available from 2022 Feb 15: https://www.pharmgkb.org/.
   Google Scholar
• Caudle KE, Klein TE, Hoffman JM, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15(2):209–217.
   PubMed Web of Science ®Google Scholar
• https://cpicpgx.org/ [Internet]. cited 2022 Feb 15
   Google Scholar
• Catarata MJ, Lourenço M, Martins MF, et al. Pharmacogenetics of advanced lung cancer: predictive value of functional genetic polymorphism AGXT Pro11Leu in clinical outcome? Pulmonology. 2021;27(2):116–123.
   PubMed Web of Science ®Google Scholar
• D’Antonio C, Milano A, Righini R, et al. Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know. Anticancer Res. 2014;34(10):5241–5250.
   PubMed Web of Science ®Google Scholar
• Papachristos A, Sivolapenko GB. Pharmacogenomics, pharmacokinetics and circulating proteins as biomarkers for bevacizumab treatment optimization in patients with cancer: a review. J Pers Med. 2020;10(3):1–20.
   Web of Science ®Google Scholar
• Nair A. Pharmacogenomics of inhalational anesthetic agents. Med Gas Res. 2019;9(1):52.
   PubMed Web of Science ®Google Scholar
• Ramroop R, Hariharan S, Chen D. Emergence delirium following sevoflurane anesthesia in adults: prospective observational study. Brazilian JAnesthesiol. 2019;69(3):233–241.
   PubMedGoogle Scholar
• Loh CH, Donohue JF, Ohar JA. Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease. Expert Opinion on Drug Safety. 2015;14(3):463–472.
   PubMed Web of Science ®Google Scholar
• Terasaki J, Nishi SP, Ameredes BT, et al. Arformoterol: rationale for use in chronic obstructive pulmonary disease. Clin Invest. 2014;4(5):429–439.
   Google Scholar
• Blake K, Lima J. Pharmacogenomics of long-acting β 2 -agonists. Expert Opin Drug Metab Toxicol. 2015;11(11):1733–1751.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. 2007, Vol. 370. England: Lancet (London;.p. 2118–2125.
   Google Scholar
• Bleecker ER, Meyers DA, Bailey WC, et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest. 2012;142(2):320–328.
   PubMed Web of Science ®Google Scholar
• Kim SH, Ye YM, Lee HY, et al. Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy. J Clin Pharm Ther. 2011;36(3):399–405.
   PubMed Web of Science ®Google Scholar
• Yelensky R, Li Y, Lewitzky S, et al. A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients. Pharmacogenomics J. 2012;12(6):484–488.
   PubMed Web of Science ®Google Scholar
• Sayers I, Hawley J, Stewart C, et al. Pharmacogenetic characterization of indacaterol, a novel β 2 -adrenoceptor agonist. Br J Pharmacol. 2009;158(1):277–286.
   PubMed Web of Science ®Google Scholar
• Whiting P, Maiwenn A, Burgers L, et al. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2014;18(18):1–106.
   Web of Science ®Google Scholar
• Cant N, Pollock N, Ford RC. CFTR structure and cystic fibrosis. Int J Biochem Cell Biol. 2014;52:15–25.
   PubMed Web of Science ®Google Scholar
• Fohner AE, McDonagh EM, Clancy JP, et al. PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics. 2017;27(1):39–42.
   PubMed Web of Science ®Google Scholar
• Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest. 2011;139(6):1480–1490.
   PubMed Web of Science ®Google Scholar
• Ronan NJ, Fleming C, O’Callaghan G, et al. The role of ivacaftor in severe cystic fibrosis in a patient with the R117H mutation. Chest. 2015;148(3):e72–5.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang X, Zhang YH, et al. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR. Drugs Today. 2016;52(4):229–237.
   PubMed Web of Science ®Google Scholar
• Clancy JP, Johnson SG, Yee SW, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype. Clin Pharmacol Ther. 2014;95(6):592–597.
   PubMed Web of Science ®Google Scholar
• Segreti A, Calzetta L, Rogliani P, et al. Umeclidinium for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2014;8(6):665–671.
   PubMed Web of Science ®Google Scholar
• Cahn A, Mehta R, Preece A, et al. Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults deficient in CYP2D6 activity: a double-blind, randomized clinical trial. Clin Drug Investig. 2013;33(9):653–664.
   PubMed Web of Science ®Google Scholar
• Mehta R, Kelleher D, Preece A, et al. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study. Int J Chron Obstruct Pulmon Dis. 2013;8:159–167.
   PubMed Web of Science ®Google Scholar
• Hosking L, Yeo A, Hoffman J, et al. Genetics plays a limited role in predicting chronic obstructive pulmonary disease treatment response and exacerbation. Respir Med. 2021;187:106573.
   PubMed Web of Science ®Google Scholar
• Condreay L, Huang L, Harris E, et al. Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease. Respir Med. 2016;114:123–126.
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M, Huddart R, Gong L, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2021;110(3):563–572.
   PubMed Web of Science ®Google Scholar
• Clinical annotation levels of evidence [Internet]. cited 2022 Oct 10]. Available from 2022 Oct 10: https://www.pharmgkb.org/page/clinAnnLevels.
   Google Scholar
• Asiimwe IG, Zhang EJ, Osanlou R, et al. Warfarin dosing algorithms: a systematic review. Br J Clin Pharmacol. 2021;87(4):1717–1729.
   PubMed Web of Science ®Google Scholar
• Lang IM, Pesavento R, Bonderman D, et al. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J. 2013;41(2):462–468.
   PubMed Web of Science ®Google Scholar
• Gordeuk VR, Castro OL, Machado RF. Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood. 2016;127(7):820.
   PubMed Web of Science ®Google Scholar
• Oldham JM, Ma SF, Martinez FJ, et al., TOLLIP, MUC5B, and the Response to N -Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2015, 192(12): 1475–1482.
   PubMed Web of Science ®Google Scholar
• Gonsalves SG, Dirksen RT, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR 1 or CACNA 1S Genotypes. Clin Pharmacol Ter. 2019;105(6):1338–1344.
   PubMed Web of Science ®Google Scholar
• Crews KR, Monte AA, Huddart R, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther. 2021;110(4):888–896.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102(3):397.
   PubMed Web of Science ®Google Scholar
• Genes-Drugs CPIC [Internet]. cited 2022 Oct 11]. Available from 2022 Oct 11: https://cpicpgx.org/genes-drugs/.
   Google Scholar
• Aquilante CL, Kao DP, Trinkley KE, et al. Clinical implementation of pharmacogenomics via a health system-wide research biobank: the University of Colorado experience. Pharmacogenomics. 2020;21(6):375–386.
   PubMed Web of Science ®Google Scholar
• Horgan D, Jansen M, Leyens L, et al., An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe. Public Health Genomics. 2014, 17(5–6): 287–298.
   PubMed Web of Science ®Google Scholar
• Bank PC, Swen JJ, Guchelaar HJ. Pharmacogenetic biomarkers for predicting drug response. Expert Rev Mol Diagn. 2014;14(6):723–735.
   PubMed Web of Science ®Google Scholar
• Crews KR, Hicks JK, Pui CH, et al. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther. 2012;92(4):467–475.
   PubMed Web of Science ®Google Scholar
• Zarei S, Costas Y, Orozco G, et al. A web-based pharmacogenomics search tool for precision medicine in perioperative care. J Pers Med. 2020;10(3):1–14.
   Web of Science ®Google Scholar
• Scotet V, L’hostis C, Férec C. The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery. Genes (Basel). 2020;11(6):589.
   PubMed Web of Science ®Google Scholar
• Irwin AN, Johnson SG, Joline BR, et al. A descriptive evaluation of warfarin use in patients with pulmonary arterial hypertension. Thromb Res. 2014;133(5):790–794.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Kamali F, Daly AK, et al. Oral anticoagulation: a critique of recent advances and controversies. Trends Pharmacol Sci. 2015;36(3):153–163.
   PubMed Web of Science ®Google Scholar
• Parry CM, Seddon G, Rogers N, et al. Pharmacogenomics and asthma treatment: acceptability to children, families and healthcare professionals. Arch Dis Child. 2022;107(4):394–399.
   PubMed Web of Science ®Google Scholar
• Sakon C, Alicea LA, Patacca H, et al., Opportunity for pharmacogenomic testing in patients with cystic fibrosis. Pediatr Pulmonol. 2022, 57(4): 903–907.
   PubMed Web of Science ®Google Scholar
• Preston IR, Roberts KE, Miller DP, et al. Effect of Warfarin treatment on survival of patients with Pulmonary Arterial Hypertension (PAH) in the registry to evaluate early and long-Term PAH disease management (REVEAL). Circulation. 2015;132(25):2403–2411.
   PubMed Web of Science ®Google Scholar
• Caldeira D, Loureiro MJ, Costa J, et al. Oral anticoagulation for pulmonary arterial hypertension: systematic review and meta-analysis. Can J Cardiol. 2014;30(8):879–887.
   PubMed Web of Science ®Google Scholar
• LLerena A. Population pharmacogenetics and global health. Drug Metabolism and Personalized Therapy. 2015;30(2):73–74.
   PubMedGoogle Scholar
• LLerena A. Pharmacogenetics in Iberoamericans and its clinical implications. JPharm Pharmacogn Res. 2014;2:S114.
   Google Scholar
• V RM, Schwab M, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT 15 genotypes: 2018 update. Clin Pharmacol Ther. 2019;105(5):1095–1105.
   PubMed Web of Science ®Google Scholar
• Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther. 2020;108(2):191–200.
   PubMed Web of Science ®Google Scholar